Semaglutide

At a glance

What is semaglutide?

Semaglutide is a synthetic peptide drug that mimics GLP-1 (glucagon-like peptide-1), a hormone your gut naturally releases after eating. It's a 31-amino-acid chain engineered with three specific modifications that extend its half-life from about 2 minutes (native GLP-1) to approximately 7 days — enabling once-weekly dosing.^[6]

Developed by Novo Nordisk in Denmark, semaglutide emerged from a systematic program that tested hundreds of GLP-1 analogs. It was compound #217 in that program. The three modifications that make it work are:

• Aib at position 8: Protects against DPP-4 enzyme degradation (what normally destroys GLP-1 in minutes)
• Arg at position 34: Prevents fatty acid binding at an unintended site
• C-18 fatty diacid at Lys26: Enables strong albumin binding, which acts as a slow-release reservoir in the blood

The result is a drug that does what natural GLP-1 does — stimulate insulin release, suppress glucagon, slow stomach emptying, and reduce appetite — but lasts long enough to be clinically useful.

Semaglutide is sold under three brand names: Ozempic (injectable, for type 2 diabetes), Wegovy (injectable and oral, for weight management and MASH), and Rybelsus (oral, for type 2 diabetes). It became a household name around 2022-2023 as its weight loss effects gained widespread media attention.

How it works

In plain terms, semaglutide tells your body three things: release more insulin (but only when blood sugar is already high), slow down digestion so you feel full longer, and reduce appetite signals in the brain. The net effect is lower blood sugar, less hunger, and significant weight loss.

What the research says

Semaglutide has been studied in more than 100 clinical trials with over 25,000 participants in pivotal Phase III programs alone. The evidence for its efficacy in weight loss, glycemic control, and cardiovascular risk reduction is among the strongest in modern medicine.

Research timeline

Semaglutide's research timeline reads like a case study in rigorous drug development — from discovery through multiple FDA approvals and indication expansions:

Key clinical trials

The sheer scale of semaglutide's clinical program is unusual — even among FDA-approved drugs. Here are the most important trials:

Emerging research

Active clinical trials are exploring semaglutide for indications beyond its current approvals:

What the evidence shows

Unlike most peptides profiled on Peptide Garden, the claims about semaglutide are largely supported by strong clinical evidence. Here's the evidence behind the most common questions:

Safety & side effects

Semaglutide's safety profile is well-characterized from thousands of patients across dozens of trials, plus post-marketing data from millions of prescriptions. The risks are real — but they are known, documented, and manageable under medical supervision.^[7]

Common side effects (from clinical trials)

Gastrointestinal effects are the most common and are dose-dependent:

• Nausea: 20-44% (vs. ~10% placebo) — typically worst during dose escalation, improves over 4-8 weeks
• Diarrhea: 15-30%
• Vomiting: 5-24%
• Constipation: 10-24%
• Abdominal pain: 5-20%

Other reported side effects include injection-site reactions, headache, fatigue, dizziness, and dyspepsia.

Serious safety concerns

• Pancreatitis: Rare but documented. GLP-1 RA users show approximately 2x risk vs. non-users in pharmacovigilance data. Contraindicated in patients with history of pancreatitis.
• Gallbladder disease: Increased risk of cholelithiasis (gallstones), confirmed across multiple trials.
• Acute kidney injury: Reported, likely secondary to dehydration from severe GI side effects. Adequate hydration is essential.
• Diabetic retinopathy: SUSTAIN 6 showed higher rate of retinopathy complications in patients with pre-existing retinopathy.
• Pulmonary aspiration during anesthesia: Since November 2024, the FDA label carries a class-wide warning about the risk of pulmonary aspiration under general anesthesia or deep sedation, because delayed gastric emptying can leave food in the stomach. Anesthesiology societies (not the FDA label) recommend holding the drug before such procedures. Tell your surgical and anesthesia team you take semaglutide.^[15]
• Gastrointestinal obstruction: Postmarketing GI adverse reactions on the label include ileus, intestinal obstruction, and severe constipation or fecal impaction.^[15]
• Muscle/lean mass loss: 25-40% of weight lost is lean mass. This is a meaningful concern, especially for older adults at risk of sarcopenia.^[12]
• Suicidal ideation — review resolved, no increased risk found: An early signal in FDA's FAERS adverse-event database prompted a multi-year FDA review starting in 2023. That review did not hold up. On January 13, 2026, the FDA closed the review, finding no increased risk of suicidal ideation or behavior across a meta-analysis of 91 placebo-controlled trials (107,910 patients) plus a large healthcare-claims cohort comparing GLP-1 users to SGLT2-inhibitor users (~2.2 million patients). The FDA ordered the suicidal-ideation language removed from the Warnings & Precautions sections of the Saxenda, Wegovy, and Zepbound labels.^[17]

Vision: NAION ("eye stroke") risk

A possible link between semaglutide and a rare optic-nerve condition called non-arteritic anterior ischemic optic neuropathy (NAION) — sometimes described as an "eye stroke" — has been one of the most discussed safety questions of the past two years. Here is where the evidence stands, kept in proportion.

In March 2026, the North American Neuro-Ophthalmology Society (NANOS) and the American Academy of Ophthalmology issued a joint clinical statement. Their measured conclusion: the association is real but observational — drawn from retrospective studies that show an association, not proof of cause. If a true increase exists, it is roughly a 2-fold relative risk and likely lower than the original 2024 study suggested. Crucially, NAION is rare to begin with, so even a doubled relative risk translates to a small absolute risk. The societies recommend shared decision-making, not universal discontinuation, and they specifically advised against automatically stopping the drug.^[18]

What that looks like in absolute numbers: an April 2026 JAMA Ophthalmology target-trial-emulation study followed 102,361 US veterans with type 2 diabetes, comparing semaglutide initiators to those starting an SGLT2 inhibitor. It found a hazard ratio of about 2.33 — but the incidence was roughly 123 per 100,000 person-years on semaglutide versus 67 per 100,000 on SGLT2 inhibitors (about 0.3% vs 0.1% cumulative risk). That is more than double the relative risk, yet still about one additional case per several thousand patients treated.^[19] A September 2025 systematic review and meta-analysis put the pooled estimate at a hazard ratio of about 2.62 (95% CI 1.81–3.80), with risk rising over longer exposure.^[20] In Europe, the EMA's safety committee (PRAC) concluded in June 2025 that NAION is a "very rare" side effect of semaglutide (up to 1 in 10,000) and recommended adding it to the EU product information.^[26]

Weight regain after discontinuation

This deserves its own section because it's one of the most important limitations:

• STEP 4: Switching to placebo after 20 weeks of semaglutide led to gradual weight regain^[4]
• STEP 1 extension: Participants regained approximately two-thirds of their weight loss within one year of stopping^[5]
• Cardiometabolic improvements (blood pressure, lipids, HbA1c) also reversed after discontinuation

This doesn't mean semaglutide "doesn't work." It means obesity is a chronic condition, and semaglutide — like medications for hypertension or high cholesterol — requires ongoing use to maintain its effects.

How people use it

Unlike most peptides profiled on Peptide Garden, semaglutide has FDA-approved dosing protocols validated in large clinical trials. These are the clinically established regimens.

FDA-approved dosing — Ozempic (injectable, type 2 diabetes)

FDA-approved dosing — Wegovy (injectable, weight management)

FDA-approved dosing — Rybelsus (oral, type 2 diabetes)

Administration routes

• Subcutaneous injection (Ozempic, Wegovy injectable): Abdomen, thigh, or upper arm. Once weekly. Comes in pre-filled pen — no reconstitution needed.
• Oral tablet (Rybelsus, Wegovy oral): Daily for Rybelsus. Approved in oral form for Wegovy as of December 2025.

Compounded semaglutide: a critical safety distinction

Key differences between FDA-approved and compounded semaglutide:

• Dosing precision: FDA-approved pens deliver exact doses. Compounded vials require manual dose measurement, leading to confusion between mg, mL, and "units" that has caused 5-20x overdoses.
• Salt form: Compounded versions may use semaglutide sodium or acetate, which may have different pharmacological properties than the active ingredient in Ozempic/Wegovy.
• Quality control: FDA-approved products undergo rigorous manufacturing standards. Compounded products have variable quality — the FDA has sent 50+ warning letters to GLP-1 compounders.
• Cost: Compounded semaglutide ($99-$500/month) is significantly cheaper than branded products (Ozempic ~$998/month, Wegovy ~$1,349/month without insurance).

Legal & regulatory status

As of June 2026:

FDA-approved indications

Semaglutide is an FDA-approved prescription drug with multiple approved indications across three brand names:

In March 2026, the FDA approved Wegovy HD — a higher-dose 7.2 mg formulation — under the Commissioner's National Priority Voucher pathway, with a US launch the following month.^[23]

Compounding status

The regulatory landscape for compounded semaglutide has changed significantly:

• During the FDA-declared shortage, compounding pharmacies could legally prepare semaglutide
• February 2026: The FDA declared the semaglutide shortage officially ended
• Post-shortage, compounding is only permitted for patients with documented medical needs (e.g., allergy to branded inactive ingredients, specific dosing requirements not available in commercial products)
• The FDA has sent 50+ warning letters to GLP-1 compounders for violations
• Tighter restrictions have reduced supply and increased prices at telehealth providers

WADA / USADA status

Semaglutide is not prohibited under WADA anti-doping rules — GLP-1s are not on the 2026 Prohibited List. It has been on WADA's Monitoring Program since 2024, meaning WADA is tracking usage patterns among athletes; for 2026 the Monitoring Program tracks markers of both semaglutide and tirzepatide. Athletes will NOT receive anti-doping violations for semaglutide use. A decision on possible prohibition is expected by the end of 2026 or in 2027, potentially ahead of the LA 2028 Olympics.

Insurance and access

• Most commercial insurance covers semaglutide for the type 2 diabetes indication
• Coverage for weight management is expanding but inconsistent
• Medicare/Medicaid coverage for obesity potentially expanding (April 2026, with a ~$50/month cap)
• Manufacturer savings cards can reduce copays to ~$25/month for eligible commercially insured patients
• Without insurance: Ozempic ~$998/month, Wegovy ~$1,349/month, Rybelsus ~$998/month

How semaglutide compares

Semaglutide vs. Tirzepatide (the most common comparison)

The SURMOUNT-5 trial provided the first head-to-head data between semaglutide and tirzepatide — the two dominant GLP-1-based weight loss drugs:^[11]

Tirzepatide achieves greater weight loss in head-to-head comparison. However, semaglutide currently has a stronger cardiovascular outcomes evidence base (SELECT trial) and more FDA-approved indications. Both drugs have similar GI side effect profiles. The choice between them is best made with a physician based on individual clinical circumstances.

Semaglutide vs. the peptide evidence standard

To understand what "strong evidence" means, compare semaglutide to a popular research peptide:

This contrast isn't meant to diminish BPC-157 — it's meant to calibrate expectations. When you see a peptide vendor claim their product has "clinical evidence," ask: how many participants? What study design? Published where? The difference between 30 participants in open-label studies and 17,604 in a double-blind RCT is the difference between "interesting signal" and "established fact."